ArticleIn vivo (Athens, Greece)

The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model.

Kihwan Hwang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.